Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- HEK-293 CD-70 27 NF?B PI-3K PI3-K P-I3K I3 CD-4 8 27L TNFSF-7
- Product Overview:
CD70, also known as CD27 ligand (CD27L), is a type II transmembrane glycoprotein and member of the tumor necrosis factor (TNF) ligand superfamily (TNFSF).{59406} It is comprised of an N-terminal extracellular domain, a transmembrane domain, a stalk region, and a C-terminal TNF homology domain and is exclusively expressed on activated T and B cells and mature dendritic cells.{59406,13302,52860} CD70 forms homotrimers and binds to its receptor, CD27 (Item No. 31828), on antigen-primed T cells, which induces NF-?B and MAPK signaling through TNF receptor-associated factors (TRAFs) and, when the T cell is stimulated by other factors, induces PI3K signaling to induce the co-stimulation and expansion of naïve CD4+ and CD8+ T cells.{54194,59406} CD70 is overexpressed in various hematological malignancies and is associated with accelerated tumor cell proliferation.{52860} CD70 expression is negatively correlated with overall survival in patients with diffuse malignant mesothelioma of the pleura. Cayman’s CD27L/CD70 Extracellular Domain (human, recombinant) protein can be used for binding assay applications. This protein is a disulfide-linked homodimer. The reduced monomer, comprised of CD70 (amino acids 39-193) fused to human IgG Fc at its N-terminus, consists of 413 amino acids and has a calculated molecular weight of 45.5 kDa. As a result of glycosylation, the monomer migrates at approximately 55-60, 110-120, and 160-170 kDa, corresponding to the monomeric, dimeric and trimeric forms, respectively, by SDS-PAGE under reducing conditions.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.